Adaptive Density-Informed AI Framework for Improving Breast Cancer Detection Using Mammography and Thermal Imaging - 14/04/26

Doi : 10.1016/j.ibreh.2026.100053 
Siva Teja Kakileti 1, , Bharath Govindaraju 1, Sudhakar Sampangi 2, Geetha Manjunath 1
1 Niramai Health Analytix Pvt Ltd, Bangalore, India 
2 HCG Cancer Hospital, Bangalore, India 

Corresponding author: Dr. Siva Teja Kakileti, Niramai Health Analytix Pvt Ltd, Koramangala, Bangalore 560095, Karnataka, India Tel No: +91 8011 280465 Niramai Health Analytix Pvt Ltd Koramangala Bangalore Karnataka 560095 India

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Tuesday 14 April 2026

Highlights

Introduces a Density-Informed Multimodal AI (DIMA) framework for breast cancer screening.
Proposes a clinically feasible AI system combining mammography and thermal imaging to overcome dense-breast limitations.
Achieves 94.6% sensitivity and 79.9% specificity in a cohort of 324 women across both dense and fatty breast types.
Employs an interpretable, rule-based fusion using breast density as a conditional decision variable.
Enables a clinically deployable, low-cost, and equitable AI pathway for breast cancer detection.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Mammographic screening performance declines in women with dense breasts, leading to diagnostic inequities and delayed cancer detection. Thermal imaging captures complementary functional cues such as vascular and metabolic activity that remain detectable irrespective of density with the help of Artificial Intelligence (AI). This study presents an adaptive Density-Informed Multimodal AI (DIMA) Framework that integrates mammography and thermal imaging to improve breast cancer detection performance across breast density categories.

Methods

The framework integrates two complementary AI pipelines: a multi-view deep learning model trained on 19,883 mammograms for morphological feature analysis, and a radiomics-based Thermalytix system trained on over 100,000 thermal images to capture vascular and thermal asymmetries. Breast density, categorized by ACR grades, functions as a conditional variable that dynamically determines which model’s prediction is used. The mammography AI is applied for fatty breasts (ACR A and B), whereas the Thermalytix AI is prioritized for dense breasts (ACR C and D). This density-conditioned decision logic enables optimal modality utilization while maintaining interpretability. To assess real-world applicability, the framework was evaluated on 324 women who underwent both mammography and thermal imaging.

Results

The DIMA framework achieved a sensitivity of 94.6% (95% CI: 88.6–100) and specificity of 79.9% (95% CI: 75.1–84.7), outperforming standalone mammography AI (sensitivity 81.8%, specificity 86.3%) and Thermalytix AI (sensitivity 92.7%, specificity 75.5%). Importantly, the sensitivity of Mammography dropped significantly in dense breasts (67.9%) versus fatty breasts (96.3%), whereas Thermalytix AI maintained high and consistent sensitivity in both (92.6% and 92.9%, respectively).

Conclusions

This retrospective cross-sectional diagnostic accuracy evaluation demonstrates the potential of a DIMA routing strategy to improve breast cancer detection across breast density categories. Population-based screening studies are required to assess its generalizability, equity, and role within large-scale screening programs.

Le texte complet de cet article est disponible en PDF.

Keywords : Breast Cancer, Mammography, Thermalytix, Thermal Imaging, Multi-modal imaging, Artificial Intelligence, Machine Learning


Plan


 This study has not been presented in any other journal.
 Conflict of interest
 Siva Teja Kakileti reports a relationship with NIRAMAI Health Analytix Pvt. Ltd. that includes employment and equity ownership. Bharath Govindaraju reports a relationship with NIRAMAI Health Analytix Pvt. Ltd. that includes employment. Sudhakar Sampangi reports a relationship with NIRAMAI Health Analytix Pvt. Ltd. that includes consulting or advisory roles and equity ownership. Geetha Manjunath reports a relationship with NIRAMAI Health Analytix Pvt. Ltd. that includes board membership, employment, and equity ownership.
 Funding Support
 This study was funded internally by Niramai Health Analytix Pvt Ltd. No external funding was received. The funding source had no role in standard-of-care interpretation, clinical decision-making, or patient management. AI analyses were performed offline and independently of clinical reporting.
 Author Contributions
 Siva Teja Kakileti: Conceptualization, Methodology, Investigation, Formal Analysis, Software, Visualization, Writing – Original Draft, Supervision.
 Bharath Govindaraju: Methodology, Formal Analysis, Data Curation, Software, Visualization, Writing – Original Draft.
 Sudhakar Sampangi: Conceptualization, Resources, Writing – Review & Editing.
 Geetha Manjunath: Conceptualization, Resources, Supervision, Writing – Review & Editing.


© 2026  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.